Adial Pharmaceuticals, Inc. (ADIL)
- Previous Close
1.7000 - Open
1.6500 - Bid 1.7000 x 400
- Ask 1.7300 x 400
- Day's Range
1.6301 - 1.7600 - 52 Week Range
0.7700 - 14.0000 - Volume
142,791 - Avg. Volume
6,515,841 - Market Cap (intraday)
6.934M - Beta (5Y Monthly) 1.53
- PE Ratio (TTM)
-- - EPS (TTM)
-4.9100 - Earnings Date May 10, 2024 - May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.00
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
www.adialpharma.comRecent News: ADIL
Performance Overview: ADIL
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADIL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADIL
Valuation Measures
Market Cap
6.93M
Enterprise Value
4.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.70
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.70
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-82.24%
Return on Equity (ttm)
-190.27%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-7M
Diluted EPS (ttm)
-4.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.83M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.21M